Women make up a majority of the group of 25 attorneys appointed by a New Jersey federal judge on January 22 to the Elmiron MDL leadership team; the team also includes a significant number of minority women and younger attorneys who have never served in leadership...
Litigation Update: Diversity Governs in Elmiron’s Plaintiff Steering Committee
Consumers in the Elmiron MDL against Johnson & Johnson (J&J) informed a New Jersey federal judge that they have chosen diverse representation to serve on the plaintiff steering committee. The committee is diverse in a number of ways, including ethnicity,...
Litigation Update: Elmiron MDL Sent to New Jersey
On Tuesday, December 15th the JPML sent all Elmiron cases to be tried in New Jersey by U.S. Judge Brian R. Martinotti. The judge had been handling Elmiron lawsuits and had already set up processes resembling those typically followed in MDLs. Because those efforts were...
Litigation Update: JPML to Decide on Elmiron’s Litigation Venue
At the last JPML hearing held on Thursday, December 4th, the panel heard from counsel for Johnson & Johnson and lawyers for plaintiffs. Both sides presented arguments for creating an MDL for all Elmiron cases in New Jersey federal court. Those proposing NJ as...
Litigation Update: Elmiron Linked to Serious Eye Injuries
Elmiron [Pentosan Polysulfate Sodium (PPS)] is a drug developed in 1996 by Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals to treat interstitial cystitis, bladder pain and osteoarthritis. The drug has been linked to serious eye injuries including...